Gilead Sciences, Inc. (GILD): A Bull Case Theory
We came across a bullish thesis on Gilead Sciences, Inc. on Dividend Talks’s Substack. In this article, we will summarize the bulls’ thesis on GILD.
Gilead Sciences Inc. (GILD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Ayrshire Capital Management John Nevin Jr. | 5,400 | $598,698 | 0.29% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $99.92 | 10,000 | $999,150.00 | 88,173 | 2015-02-06 | Filing | |
| $43.05 | 10,000 | $430,493.00 | 69,458 | 2013-02-28 | Filing | |
| $44.00 | 10,000 | $439,955.00 | 26,097 | 2012-02-22 | Filing | |
| $38.60 | 8,704 | $335,974.40 | 12,800 | 2010-05-04 | Filing | |
| $38.59 | 4,096 | $158,064.64 | 4,096 | 2010-05-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $111.15 | 600 | $66,688.02 | 615,725 | 2025-06-30 | Filing | |
| $110.40 | 9,400 | $1,037,795.72 | 616,325 | 2025-06-30 | Filing | |
| $110.17 | 2,500 | $275,425.00 | 165,110 | 2025-06-16 | Filing | |
| $110.17 | 3,000 | $330,510.00 | 120,168 | 2025-06-16 | Filing | |
| $110.96 | 3,584 | $397,696.05 | 620,268 | 2025-05-30 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,403,630 | $266,490,459 | 0.3% | |
| 2. | 1,319,796 | $146,325,783 | 0.22% | |
| 3. | 969,807 | $107,522,447 | 1.52% | |
| 4. | 663,697 | $73,584,133 | 2.33% | |
| 5. | 484,018 | $54,088,943 | 0.09% |
News See All
Gilead Sciences, Inc. (GILD) Reports Advances in HIV Treatment with Phase 2/3 Clinical Trial Update
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio.
Gilead Sciences (GILD) Announces that US FDA Approves Yeztugo®as pre-exposure prophylaxis (PrEP)
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 10 Best Value Stocks to Buy According to Billionaires.
10 Best Value Stocks to Buy According to Billionaires
The H1 2025 has been a roller coaster ride for the investors. During the initial months of the year, the benchmarks touched record highs, according to Bank of America Private Bank.
10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio
Ray Dalio began his investing journey at just 12 years old and went on to gain experience at institutions such as the New York Stock Exchange, Dominick & Dominick LLC, and Shearson Hayden Stone.
Gilead, Kymera Partner in $750M Deal to Develop Novel Molecular Glue Degraders for Cancer
Gilead Sciences Inc. (NASDAQ:GILD) is one of the undervalued S&P 500 stocks to buy according to hedge funds.
10 Undervalued S&P 500 Stocks to Buy According to Hedge Funds
On June 24, Paul Hickey, Bespoke Investment Group co-founder, joined 'Squawk Box' on CNBC to suggest that periods of widespread fear often present good buying opportunities.
Gilead (GILD) Downplays FDA Decision to Pause HIV Combination Trial over Safety Concern
Gilead Sciences Inc. (NASDAQ:GILD) is one of the 12 best healthcare stocks to buy now.
12 Best Healthcare Stocks to Buy Now
Healthcare companies in the US are facing policy headwinds under President Donald Trump's Administration.
Goldman Sachs Reiterates a Hold Rating on Gilead Sciences (GILD)
Gilead Sciences, Inc. (NASDAQ:GILD) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Goldman Sachs analyst Salveen Richter reiterated a Hold rating on Gilead Sciences, Inc.
Billionaire Hedge Funds
